Codes2002 - Autoantibodies in Acute Viral Hepatitis

Full citation: Codes L, Santos de Jesus R, Cunha S, Cruz M, Paraná R. Freqüência e implicações dos auto-anticorpos em hepatites agudas virais [Frequency and implications of autoantibodies in acute viral hepatitis]. Revista da Sociedade Brasileira de Medicina Tropical 35(5): 465–469, 2002.

Raw file: [[raw/codes2002.pdf]]

Note: This is NOT a dengue paper. It is a viral hepatitis study (HAV/HBV/HCV/HEV/non A-E) included in this wiki because it provides the primary sourced data for the 20.5% acute-phase ANA / 6.4% convalescence ANA figures cited across multiple pages as a comparator baseline for infection-triggered ANA transience.

Summary

This prospective study enrolled 156 patients with acute viral hepatitis at the hepatology outpatient clinic of the Universidade Federal da Bahia (UFBA), Salvador, Brazil, from 1992 to 2000. Patients were classified by aetiology (HAV 32.7%, HBV 31.4%, HCV 8.3%, HEV 3.2%, non A-E 24.4%) and followed for 6 months, with ANA and anti-smooth muscle antibody (ASMA) measured by indirect immunofluorescence (IIF) in the acute phase and at 30 and 90 days.

The central finding is that 20.5% of patients were ANA-positive (homogeneous pattern, ≥1:40) during the acute phase, declining to 6.4% at 90-day convalescence. Similarly, 14.8% were ASMA-positive acutely, declining to 3.9% at convalescence. Crucially, no statistically significant differences in ALT or bilirubin levels were found between autoantibody-positive and negative patients, and there was no association with chronification risk in HBV, HCV, or non A-E hepatitis.

The authors conclude that autoantibodies appearing during acute viral hepatitis are transient epiphenomena of hepatocellular injury rather than prognostic markers or drivers of chronicity.

Study Design

• Type: Prospective cohort
• Sample size: n=156
• Setting: Hepatology outpatient clinic, UFBA, Salvador, Bahia, Brazil; 1992–2000
• Population: Adults (mean age 27.6 ± 14.2 years; 55.8% male) with acute viral hepatitis; prior hepatotoxic drug use, biliary obstruction, CCF, excessive alcohol, or other hepatic causes excluded

Key Findings

• ANA acute phase: 32/156 (20.5%) positive, homogeneous pattern, ≥1:40; all at low titre (≤1:80)
• ANA convalescence (90 days): 10/156 (6.4%) still positive, all at low titre (≤1:40)
• Anti-smooth muscle antibody (ASMA) acute: 23/156 (14.8%) positive, ≥1:40
• ASMA convalescence: 6/156 (3.9%) positive, ≤1:40
• Severity independence: No statistically significant difference in ALT or bilirubin between ANA+ and ANA− groups (Mann-Whitney test, p>0.05) in acute phase or convalescence
• Chronification: No association between autoantibody positivity and hepatitis chronification (HBV, HCV, non A-E)
• Sex/age: No difference between autoantibody-positive and negative groups
• Most antibodies returned to normal by 30 days; the small proportion persisting to 90 days showed no clinical correlate
• Interpretation: autoantibodies are consequence rather than cause of hepatic injury; epiphenomena of cellular damage exposing normally sequestered self-antigens

Methods Used

• Indirect Immunofluorescence ANA Test — IIF used for both ANA (FAN = Fator Antinúcleo) and ASMA testing; measured acutely and repeated at 30 and 90 days
• Biochemical panel: ALT, ALP, GGT, prothrombin time, total bilirubin (every 15 days for 3 months, then monthly to 6 months)
• Serological diagnosis: IgM anti-HAV, HBsAg, IgM anti-HBc, anti-HCV, anti-HEV (Abbott commercial kits); HCV-RNA for acute HCV confirmation; IgM anti-EBV and IgM anti-CMV to exclude CMV/EBV (Biomerieux)
• Statistical: Mann-Whitney test; chi-square or Fisher’s test; SPSS 9.01

Entities Mentioned

(No dengue-specific entities; included as comparator baseline)

Concepts Addressed

• Infection-Triggered Autoimmunity — primary contribution: quantified acute→convalescent ANA transience in a prospective viral hepatitis cohort; mechanisms discussed (antigen modification, molecular mimicry, lymphocyte subpopulation dysregulation, inflammatory mediator amplification)
• Antinuclear Antibodies — provides sourced 20.5% acute / 6.4% convalescent rate in acute viral hepatitis; homogeneous pattern at low titre
• Autoimmunity in Dengue — cited as background comparator context

Relevance & Notes

This paper is the primary source for the 20.5% acute-phase / 6.4% convalescence ANA figures that appear across several wiki pages, previously attributed as “a study cited by Berlin2007” without a full reference. Berlin2007 cites this result but does not identify it as Codes2002 in the wiki’s prior text.

The key comparator value for the dengue ANA thread is: any acute viral infection produces ANA in ~1 in 5 patients by IIF at ≥1:40, and these resolve within 90 days in ~70% of the initially positive group. Dengue ANA data must be interpreted against this viral-infection baseline, not just against the healthy-population baseline (13.8–16.1% at 1:80). The ~5-fold difference between Chatterjee2024’s 54.8% dengue IIFA rate and Codes2002’s 20.5% hepatitis IIF rate may or may not be meaningful given different cutoffs (both ≥1:40 in Codes2002; varying in Chatterjee2024), different patient populations, and different substrates.

The paper also documents ASMA elevation during acute viral hepatitis (14.8% → 3.9%), a finding not typically discussed in dengue literature. Whether dengue produces similar transient ASMA elevation is unknown.

The mechanism discussion (pp. 468) explicitly covers molecular mimicry and viral antigen modification — directly parallel to mechanisms discussed in dengue autoimmunity papers (see NS1 Molecular Mimicry in Dengue, Johnson2022 - Infectious Diseases Autoantibodies and Autoimmunity).

Limitation: ANA cutoff of ≥1:40 is below the internationally recommended clinical cutoff of ≥1:80 (Aringer2019, Tan1997). This makes the 20.5% acute-phase rate not directly comparable to studies using ≥1:80 as the threshold. At ≥1:80 (the only positive subgroup in their data), the rate would be the 4.5% (7/156) with 1:80 homogeneous pattern — substantially lower. This distinction is critical when using Codes2002 as a benchmark.

Questions Raised

• Does dengue specifically produce higher ANA positivity than other acute viral infections at matched thresholds and substrates? Codes2002 (hepatitis, ≥1:40 IIF) and Chatterjee2024 (dengue, HEp-2 IIFA) are not directly comparable without a matched-design study.
• Does dengue produce transient ASMA elevation as seen in hepatitis? No dengue study in this wiki has measured ASMA.
• Is the ≥1:80 acute rate in hepatitis (≈4.5%) comparable to the ≥1:80 rate in dengue? No study in this wiki reports dengue ANA at the ≥1:80 threshold in the acute phase using a matched platform.